The FDA has authorized urcosimod 0.05% for single-patient expanded access, or compassionate use, in a patient with neuropathic corneal pain, according to a press release from Okyo.
The terms of the Investigational New Drug (IND) application stipulate that urcosimod will be provided by the company to be used in a patient with limited therapeutic options and no FDA-approved treatment options.
“We are grateful that this FDA authorization allows us to explore the potential of urcosimod in a patient with severe neuropathic corneal pain through a physician-sponsored expanded access IND,”